Who is on it, and how far along Every drug ChEMBL records acting on ABCC8, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved10 Repaglinide Repaglinide SponsorGemini Labs ModalitySmall molecule ActionBlocker Open trials9 Gliclazide Gliclazide SponsorMerck & Co. (MSD) ModalitySmall molecule ActionBlocker Open trials5 Glimepiride Glimepiride SponsorSanofi ModalitySmall molecule ActionBlocker Open trials5 Glyburide Glyburide SponsorPfizer ModalitySmall molecule ActionBlocker Open trials5 Glipizide Glipizide SponsorPfizer ModalitySmall molecule ActionBlocker Open trials4 Tolbutamide Tolbutamide SponsorJiangsu Simcere Pharmaceutical Co., Ltd. ModalitySmall molecule ActionBlocker Open trials1 Acetohexamide Acetohexamide SponsorEli Lilly ModalitySmall molecule ActionBlocker Open trials0 Chlorpropamide Chlorpropamide SponsorPfizer ModalitySmall molecule ActionBlocker Open trials0 Nateglinide Nateglinide SponsorNovartis Pharmaceuticals ModalitySmall molecule ActionBlocker Open trials0 Tolazamide Tolazamide SponsorPfizer ModalitySmall molecule ActionBlocker Open trials0 Phase 32 Mitiglinide Mitiglinide SponsorElixir Pharmaceuticals ModalitySmall molecule ActionBlocker Open trials0 Mitiglinide calcium dihydrate Mitiglinide calcium dihydrate SponsorKissei Pharmaceutical Co., Ltd. ModalityOther ActionBlocker Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Sulfonylurea receptor 1, Kir6.2 blocker. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes Gliclazide Phase 2 Recruiting Universitas Sriwijaya Nov 10, 2026 Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Repaglinide, Tolbutamide Phase 1 Not yet recruiting Jiangsu Simcere Pharmaceutical Co., Ltd. Nov 3, 2026 A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Glimepiride, Glipizide, Gliclazide Phase 2 Active, not recruiting Beijing University of Chinese Medicine Oct 30, 2026 A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects Repaglinide Phase 1 Recruiting Basilea Pharmaceutica Oct 19, 2026 Comparison of Metformin Versus Glyburide for Blood Sugar Control in Women With Gestational Diabetes Glyburide Phase 4 Recruiting Nishtar Medical University Sep 3, 2026 Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Repaglinide Phase 4 Recruiting Rigel Pharmaceuticals Jul 15, 2026 Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3 Glimepiride Not applicable Recruiting Washington University School of Medicine May 15, 2026 A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. Repaglinide Phase 1 Recruiting PMV Pharmaceuticals, Inc Jan 28, 2026 Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Glimepiride Phase 4 Not yet recruiting Chong Kun Dang Pharmaceutical Jan 26, 2026 A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies Repaglinide Phase 1 Recruiting Novartis Pharmaceuticals Jan 14, 2026 Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction. Glimepiride Phase 3 Not yet recruiting Tongji Hospital Dec 17, 2025 OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis Glyburide Phase 1 Not yet recruiting University of Maryland, Baltimore Oct 28, 2025 A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors Repaglinide Phase 1 / Phase 2 Recruiting Verastem, Inc. Jun 13, 2025 Diabetes Management for Primary Healthcare Centers. Glyburide Not applicable Active, not recruiting University of Abuja Apr 2, 2025 Role of KATP Channel Loss in Type 2 Diabetes Glipizide Not applicable Recruiting Washington University School of Medicine Feb 17, 2025 Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients Repaglinide, Gliclazide Early phase 1 Not yet recruiting Liu Zhanghong Jan 28, 2025 Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes Gliclazide Phase 4 Recruiting University Medical Centre Ljubljana Sep 26, 2024 A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer Glipizide Phase 2 Active, not recruiting Memorial Sloan Kettering Cancer Center Dec 13, 2023 Spinal Cord Injury Neuroprotection With Glyburide Glyburide Phase 1 Recruiting Francis Farhadi Jun 22, 2022 A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) Repaglinide Phase 1 / Phase 2 Recruiting Nuvalent Inc. May 20, 2022 Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study Glimepiride, Glipizide, Glyburide — Active, not recruiting Brigham and Women's Hospital Feb 2, 2022 HbA1c Variability in Type II Diabetes Gliclazide Not applicable Active, not recruiting Weill Cornell Medical College in Qatar Aug 25, 2016
Show all 22Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2096972 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-19. ChEMBL and Open Targets